

Product comparison: the risk associated with multiple testing

Thomas Verron¹, Xavier Cahours¹, Stéphane Colard^{1,2}

¹*SEITA, Imperial Tobacco Group - France*

²*Imperial Tobacco Limited - U.K.*

Context

- Manufacturers are increasingly being asked by regulatory authorities to report data on their products
- The objective of these requests is to use data for
 - Public communication
 - Product comparison
 - Introduction of smoke yield ceilings

Context

- Manufacturers are increasingly being asked by regulatory authorities to report data on their products
- The objective of these requests is to use data for
 - Public communication
 - **Product comparison**
 - Introduction of smoke yield ceilings




Health Canada - Testing of 44 smoke emissions

Other Regulatory Authorities
e.g. in Taiwan, Brazil, China, etc –

EU: Directive 2001/37/CE, to report 3 smoke constituents (TAR, CO, Nicotine)

FDA - Testing of HPHCs proposed on a shortlist 20 constituents and an extended list of 93 constituents

WHO / TobReg Proposed ceilings on 9 initial smoke toxicants and an extended list of 38 'priority toxicants' for monitoring and regulating



Product comparison

Context:

Product comparison



Objective:
Make a decision



Product comparison

Context:

Product comparison

2013, we showed*:



ISO, CRM...

validated and standardised
methods



Objective:
Make a decision




* B. Teillet, X. Cahours, T. Verron, S. Colard, S. Purkis. Comparison of Smoke Yield Data Collected from Different Laboratories. Beitr. Tabakforsch. Int. 25 (2013) 663-670.

Product comparison

Context:

Product comparison

2013, we showed*:




* B. Teillet, X. Cahours, T. Verron, S. Colard, S. Purkis. Comparison of Smoke Yield Data Collected from Different Laboratories. Beitr. Tabakforsch. Int. 25 (2013) 663-670.

Product comparison

Context:

Product comparison

2013, we showed*:



* B. Teillet, X. Cahours, T. Verron, S. Colard, S. Purkis. Comparison of Smoke Yield Data Collected from Different Laboratories. Beitr. Tabakforsch. Int. 25 (2013) 663-670.


Critical Difference (CD)

Maximum difference expected between two final values with a specified probability

$$|\overline{X}_A - \overline{X}_B| \leq CD = \sqrt{(2\sqrt{2}\sigma)^2 - (2\sqrt{2}\sigma_r)^2 \left(1 - \frac{1}{2n_A} - \frac{1}{2n_B}\right)}$$

Critical Difference (CD)

Maximum difference expected between two final values with a specified probability



Critical Difference (CD)

Maximum difference expected between two final values with a specified probability

$$|\overline{X}_A - \overline{X}_B| \leq CD = \sqrt{(2\sqrt{2}\sigma)^2 - (2\sqrt{2}\sigma_r)^2 \left(1 - \frac{1}{2n_A} - \frac{1}{2n_B}\right)}$$

Number of *replicates*

Critical Difference (CD)

Maximum difference expected between two final values with a specified probability

$$|\overline{X}_A - \overline{X}_B| \leq CD = \sqrt{(2\sqrt{2}\sigma)^2 - (2\sqrt{2}\sigma_r)^2 \left(1 - \frac{1}{2n_A} - \frac{1}{2n_B}\right)}$$

*Standard deviation
of repeatability*

Number of replicates

Critical Difference (CD)

Maximum difference expected between two final values with a specified probability

$$|\overline{X}_A - \overline{X}_B| \leq CD = \sqrt{\overbrace{(2\sqrt{2}\sigma)^2 - (2\sqrt{2}\sigma_r)^2}^{\text{Standard deviation of repeatability}} \left(1 - \frac{1}{2n_A} - \frac{1}{2n_B}\right)}$$

Standard deviation
Number of replicates

repeatability

Measured in the same lab
(short period of time)

$\sigma = \sigma_r$

Intermediate precision

Measured in the same lab
(long period of time*)

$\sigma = \sigma_{IP}$

Reproducibility

Measured in two labs*

$\sigma = \sigma_R$

\leq

* Assumed that the same method and protocol are used

Critical Difference (CD)

Maximum difference expected between two final values with a specified probability

Risk to have a false positive: 5%

Risk to conclude that the yields of the two products are **not equivalent** whereas actually they are.

Standard deviation
of repeatability

$$|\bar{X}_A - \bar{X}_B| \leq CD = \sqrt{(2\sqrt{2}\sigma)^2 - (2\sqrt{2}\sigma_r)^2 \left(1 - \frac{1}{2n_A} - \frac{1}{2n_B}\right)}$$

Standard deviation
Number of replicates

repeatability

Measured in the same lab
(short period of time)

$\sigma = \sigma_r$

Intermediate
precision

Measured in the same lab
(long period of time*)

$\sigma = \sigma_{IP}$

Reproducibility

Measured in two labs*

$\sigma = \sigma_R$

\leq

* Assumed that the same method and protocol are used

Product comparison

Two products are equivalent for several smoke analytes, if for each smoke analyte there are not significant differences



CD controls **“Local”** risk of concluding **for one smoke analyte** that the two products are not equivalent whereas actually they are.




Product comparison

Two products are equivalent for several smoke analytes, if for each smoke analyte there are not significant differences


➔ CD controls **“Local”** risk of concluding **for one smoke analyte** that the two products are not equivalent whereas actually they are.

➔ We want to control **“Global”** risk of concluding when **considering all smoke analytes**, that the two products are not equivalent whereas actually they are.




Product comparison

Let A and B be two equivalent products for **one smoke analyte** i.e.TAR




Product comparison

Let A and B be two equivalent products for one smoke analyte i.e.TAR



Product comparison


Let A and B be two equivalent products for **two smoke analytes i.e. TAR & NIC**



Product comparison

Let A and B be two equivalent products for **two smoke analytes i.e.TAR & NIC**


Reality **TAR** Decision Reality **NIC** Decision **Product decision**



global risk


Product comparison

Let A and B be two equivalent products for **two smoke analytes** i.e. **TAR & NIC**




Product comparison

Let A and B be two equivalent products for **two smoke analytes** i.e. **TAR & NIC**



Product comparison vs number of analytes


% of chance to make a *wrong decision**



***wrong decision** = when it is concluded that two products are not equivalent when actually they are

Product comparison vs number of analytes


% of chance to make a *wrong decision**



***wrong decision** = when it is concluded that two products are not equivalent when actually they are

Product comparison vs number of analytes

% of chance to make a *wrong decision**




***wrong decision** = when it is concluded that two products are not equivalent when actually they are

How to address the multiplicity problem

Objective:

Minimize the chance of obtaining falsely significant findings



Two simulations



- Comparison of two equivalent products considering several analytes with and without correction

% of wrong decision in function of number of analytes




- Comparison of two different products considering several analytes with corrections


% to detect a difference in function of the number of analytes



Simulation 1 : Two equivalent products



Repeat 500X



No. analyte

- 1
- 3
- 9
- 20
- 44
- 93

Comparison of A and B using

- No correction
- Bonferroni
- BH

Two products are equivalent?




% of wrong decision*
in function
of number
of analytes

*wrong decision = when it is concluded that two products are not equivalent when actually they are



Simulation 1: two equivalent products

% of wrong decision in function of the number of analytes




Without adjustment the risk to make false conclusion increase with the number of analytes



Simulation 1: two equivalent products

% of wrong decision in function of the number of analytes



Without adjustment the risk to make false conclusion increase with the number of analytes

Modification of the level of statistical significance minimises false positives
(risk to conclude that the two products are not equivalent whereas actually they are)


 **Bonferroni adjustment**



 **BH adjustment**




Simulation 2: Capacity to detect a difference between two different products on one analyte







Simulation 2: Capacity to detect a difference between two different products on one analyte



Repeat 500X



No. analyte

- 3
- 9
- 20
- 38
- 44
- 93

Comparison of A and B using

- Bonferroni
- BH




Two products are equivalent?



% to detect a difference (d) in function of the number of analytes









Simulation 2: Capacity to detect a difference between two different products on one analyte





Simulation 2: Capacity to detect a difference between two different products on one analyte



Sensitivity for detecting a difference between the two products decrease with the number of smoke analytes for a given effect size “d”.

The more analytes considered in the comparison, the more difficult to detect a difference between the two products

■ Bonferroni adjustment

=

■ BH adjustment

Conclusions

- **Critical difference (ISO 5725) is the best way** to consider the variability of measurements and laboratories in the comparison of two products for one analyte.
- In multiple testing the critical difference can be used but the **risk must be adjusted** in order to avoid false conclusion about equivalence.



Reduce the number of analytes and select carefully analytes to assure a good statistical power level in order to detect non-equivalent products.



Château Frontenac,
Québec City, Canada
October 12-16, 2014

Thank you for your attention

Some references:

- Bland JM, Altman DG. *Multiple significance tests: The Bonferroni method*. British Medical Journal 1995;310:170
- Benjamini Y, Hochberg Y. *Controlling the false discovery rate: A practical and powerful approach to multiple testing*. J R Stat Soc 1995;57:289-300
- Benjamini Y, Yekutieli D. *The control of the false discovery rate in multiple testing under dependency*. Annals of Statistics 2001;29:1165-88

www.imperialtobaccoscience.com